Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Devan V Mehrotra

Showing results (41-50 of 76) with videos related to

Pageof 8
Sort By:
NPJ Genomic Medicine|June 10, 2022
A statistical perspective on baseline adjustment in pharmacogenomic genome-wide association studies of quantitative changeHong Zhang, Aparna Chhibber, Peter M Shaw, et al.
Statistics in Medicine|July 18, 2009
Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials?Guanghan F Liu, Kaifeng Lu, Robin Mogg, et al.
Contemporary Clinical Trials|October 3, 2017
A 2-in-1 adaptive phase 2/3 design for expedited oncology drug developmentCong Chen, Keaven Anderson, Devan V Mehrotra, et al.
Statistics in Medicine|July 8, 2022
CAPITAL: Optimal subgroup identification via constrained policy tree searchHengrui Cai, Wenbin Lu, Rachel Marceau West, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 19, 2020
Evaluating the Efficacy of Coronavirus Disease 2019 VaccinesDan-Yu Lin, Donglin Zeng, Devan V Mehrotra, et al.
Statistical Methods in Medical Research|July 31, 2023
Statistical assessment of biomarker replicability using MAJAR methodYuhan Xie, Song Zhai, Wei Jiang, et al.
Nature Communications|June 7, 2020
Multi-trait analysis of rare-variant association summary statistics using MTARLan Luo, Judong Shen, Hong Zhang, et al.
Contemporary Clinical Trials|March 26, 2017
How many tumor indications should be initially screened in development of next generation immunotherapies?Cong Chen, Qiqi Deng, Linchen He, et al.
The Annals of Applied Statistics|February 24, 2022
VCSEL: PRIORITIZING SNP-SET BY PENALIZED VARIANCE COMPONENT SELECTIONJuhyun Kim, Judong Shen, Anran Wang, et al.
Pharmaceutical Statistics|February 24, 2021
Principal stratum strategy: Potential role in drug developmentBjörn Bornkamp, Kaspar Rufibach, Jianchang Lin, et al.
Pageof 8

Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
NPJ Genomic Medicine|June 10, 2022
A statistical perspective on baseline adjustment in pharmacogenomic genome-wide association studies of quantitative changeHong Zhang, Aparna Chhibber, Peter M Shaw, et al.
Statistics in Medicine|July 18, 2009
Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials?Guanghan F Liu, Kaifeng Lu, Robin Mogg, et al.
Contemporary Clinical Trials|October 3, 2017
A 2-in-1 adaptive phase 2/3 design for expedited oncology drug developmentCong Chen, Keaven Anderson, Devan V Mehrotra, et al.
Statistics in Medicine|July 8, 2022
CAPITAL: Optimal subgroup identification via constrained policy tree searchHengrui Cai, Wenbin Lu, Rachel Marceau West, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 19, 2020
Evaluating the Efficacy of Coronavirus Disease 2019 VaccinesDan-Yu Lin, Donglin Zeng, Devan V Mehrotra, et al.
Statistical Methods in Medical Research|July 31, 2023
Statistical assessment of biomarker replicability using MAJAR methodYuhan Xie, Song Zhai, Wei Jiang, et al.
Nature Communications|June 7, 2020
Multi-trait analysis of rare-variant association summary statistics using MTARLan Luo, Judong Shen, Hong Zhang, et al.
Contemporary Clinical Trials|March 26, 2017
How many tumor indications should be initially screened in development of next generation immunotherapies?Cong Chen, Qiqi Deng, Linchen He, et al.
The Annals of Applied Statistics|February 24, 2022
VCSEL: PRIORITIZING SNP-SET BY PENALIZED VARIANCE COMPONENT SELECTIONJuhyun Kim, Judong Shen, Anran Wang, et al.
Pharmaceutical Statistics|February 24, 2021
Principal stratum strategy: Potential role in drug developmentBjörn Bornkamp, Kaspar Rufibach, Jianchang Lin, et al.
Pageof 8